Literature DB >> 31393596

Osimertinib confers potent binding affinity to EGFR kinase domain duplication.

Rui Jin1, Jie Li2, Zhou Jin1, Yuefei Lu1, Yang W Shao3, Wen Li1, Guofang Zhao2, Yang Xia1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31393596     DOI： 10.1002/ijc.32617

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  3 in total

1.  The landscape of kinase domain duplication in Chinese lung cancer patients.

Authors:  Di Wu; Yuancai Xie; Chang'e Jin; Jinfan Qiu; Ting Hou; Haiwei Du; Songan Chen; Jianxing Xiang; Xi Shi; Junling Liu
Journal:  Ann Transl Med       Date:  2020-12

2.  Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report.

Authors:  Jie Li; Junrong Yan; Ran Cao; Guanjun Du; Guofang Zhao
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

3.  Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.

Authors:  Esuteru Hirokawa; Satomi Watanabe; Kazuko Sakai; Masayuki Takeda; Chihiro Sato; Takayuki Takahama; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  Thorac Cancer       Date:  2021-07-09       Impact factor: 3.500
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.